<DOC>
	<DOC>NCT01323140</DOC>
	<brief_summary>Watson's testosterone transdermal system delivers male sex hormone through skin for the treatment of men with sex hormone insufficiency.</brief_summary>
	<brief_title>Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems</brief_title>
	<detailed_description>The present study is designed to characterize efficacy and safety of testosterone from the Watson's testosterone matrix transdermal system (TMTS).</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male, 18 65 years of age; Documented testosterone deficiency; BMI 18 to 33. Evidence of prostate cancer and benign prostate hyperplasia; Taking medications that interfere testosterone metabolism; History of alcohol or drug substance abuse; Abnormal ECG; Allergic to transdermal products; Skin condition that interfere transdermal system application and assessment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>hypogonadism, testosterone, transdermal system</keyword>
</DOC>